Compass Therapeutics

About Compass Therapeutics

Compass Therapeutics is focused on developing next-generation antibodies into transformative cancer therapies to improve patients' lives. They leverage their understanding of the tumor microenvironment to create product candidates that optimize critical components for effective anti-tumor responses.

Products & Services

Therapeutic Platforms:Platforms that enable the identification of therapeutic leads with exceptional speed and diversity.

Pipeline Candidates:A robust portfolio of therapeutic candidates bridging the innate and adaptive immune system.

Clinical Trials:Ongoing clinical trials including programs like COMPANION-002, COMPANION-003, and CTX-8371.

Specialties

Antibody Development Cancer Therapies Tumor Microenvironment Research Innate and Adaptive Immune System Bridging

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 120000000 MR: - FA: approximately $120 million FAN: 120000000	D: 2025-08-12 FD: 2025-08-12	8 investors

Public Offering Latest

2025-08-12

$120.0M

8 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Thomas J. Schuetz

Chief Executive Officer

B

Barry Shin

Chief Financial Officer

J

Jonathan Anderman

Senior Vice President, General Counsel and Corporate Secretary

B

Bing Gong

Senior Vice President of Discovery Research

K

Karin Herrera

Senior Vice President and Head of Clinical Operations

N

Neil Lerner

Senior Vice President, Chief Accounting Officer

View 19 more team members with Pro

Unlock Full Team Directory

Recent News